Latest News and Press Releases

Icosavax, Inc. Announces Agreement to be Acquired by AstraZeneca

Icosavax Announces Positive Topline Interim Phase 2 Results for Combination VLP Vaccine Candidate IVX-A12 Against RSV and hMPV in Older Adults

- Reported positive twelve-month durability data and initial proof-of-concept for revaccination with IVX-121 against RSV - - IVX-A12 (RSV+hMPV) Phase 2 topline interim data expected by end of 2023...

SEATTLE, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines...

SEATTLE, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines...

SEATTLE, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines...

- Positive topline interim Phase 1 results for bivalent VLP vaccine candidate IVX-A12 against RSV and hMPV in older adults - - Positive twelve-month immunogenicity data and initial proof-of-concept...

- In new data from Icosavax’s IVX-121 Phase 1b extension trial in older adults, GMTs against RSV through day 365 persisted at ~45-70% of the GMTs at day 28 (for 75 and 250 µg unadjuvanted dosages) - ...

- Phase 2 topline interim results expected in 1Q 2024 - - 6-month durability data for Phase 1 trial of IVX-A12 also expected in 1Q 2024 - SEATTLE, June 20, 2023 (GLOBE NEWSWIRE) --...

SEATTLE, May 22, 2023 (GLOBE NEWSWIRE) -- Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines...